The Role of Diet and Nutrient Composition in Nonalcoholic Fatty Liver Disease

Journal of the Academy of Nutrition and Dietetics

Volumn 112, Issue 3, 2012, Pages 401-409

  McCarthy, Erin Marie ^a   Rinella, Mary E ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Fatty liver; NAFLD NASH; Nutrition; Obesity

Indexed keywords

EID: 84857668720     PISSN: 22122672     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jada.2011.10.007     Document Type: Article

References (109)

1. Matteoni C.A., Younossi Z.M., Gramlich T., Boparai N., Liu Y.C., McCullough A.J. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999, 116(6):1413-1419.
2. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37(4):917-923.
3. Dandona P., Aljada A., Bandyopadhyay A. Inflammation: The link between insulin resistance, obesity and diabetes. Trends Immunol 2004, 25(1):4-7.
4. Kaplan L.M. Leptin, obesity, and liver disease. Gastroenterology 1998, 115(4):997-1001.
5. Zivkovic A.M., German J.B., Sanyal A.J. Comparative review of diets for the metabolic syndrome: Implications for nonalcoholic fatty liver disease. Am J Clin Nutr 2007, 86(2):285-300.
6. Capristo E., Miele L., Forgione A., et al. Nutritional aspects in patients with non-alcoholic steatohepatitis (NASH). Eur Rev Med Pharmacol Sci 2005, 9(5):265-268.
7. Park H.S., Kim M.W., Shin E.S. Effect of weight control on hepatic abnormalities in obese patients with fatty liver. J Korean Med Sci 1995, 10(6):414-421.
8. Andersen T., Gluud C., Franzmann M.B., Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991, 12(2):224-229.
9. Ueno T., Sugawara H., Sujaku K., et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997, 27(1):103-107.
10. Huang M.A., Greenson J.K., Chao C., et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: A pilot study. Am J Gastroenterol 2005, 100(5):1072-1081.
11. Promrat K., Kleiner D.E., Niemeier H.M., et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010, 51(1):121-129.
12. Clark J.M. Weight loss as a treatment for nonalcoholic fatty liver disease. J Clin Gastroenterol 2006, 40(suppl 1):S39-S43.
13. Luyckx F.H., Desaive C., Thiry A., et al. Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998, 22(3):222-226.
14. Cotler S.J., Vitello J.M., Guzman G., Testa G., Benedetti E., Layden T.J. Hepatic decompensation after gastric bypass surgery for severe obesity. Dig Dis Sci 2004, 49(10):1563-1568.
15. Yamamoto M., Iwasa M., Iwata K., et al. Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2007, 22(4):498-503.
16. Kim C.H., Younossi Z.M. Nonalcoholic fatty liver disease: A manifestation of the metabolic syndrome. Cleve Clin J Med 2008, 75(10):721-728.
17. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998, 158(17):1855-1867.
18. Strychar I. Diet in the management of weight loss. Can Med Assoc J 2006, 174(1):56-63.
19. Appel L.J., Moore T.J., Obarzanek E., et al. A clinical trial of the effects of dietary patterns on blood pressure. N Engl J Med 1997, 336(16):1117-1124. DASH Collaborative Research Group.
20. Zhao G., Etherton T.D., Martin K.R., West S.G., Gillies P.J., Kris-Etherton P.M. Dietary alpha-linolenic acid reduces inflammatory and lipid cardiovascular risk factors in hypercholesterolemic men and women. J Nutr 2004, 134(11):2991-2997.
21. Stern L., Iqbal N., Seshadri P., et al. The effects of low-carbohydrate versus conventional weight loss diets in severely obese adults: One-year follow-up of a randomized trial. Ann Intern Med 2004, 140(10):778-785.
22. York L.W., Puthalapattu S., Wu G.Y. Nonalcoholic fatty liver disease and low-carbohydrate diets. Annu Rev Nutr 2009, 29:365-379.
23. Garg A., Bantle J.P., Henry R.R., et al. Effects of varying carbohydrate content of diet in patients with non-insulin-dependent diabetes mellitus. JAMA 1994, 271(18):1421-1428.
24. McLaughlin T., Abbasi F., Lamendola C., Yeni-Komshian H., Reaven G. Carbohydrate-induced hypertriglyceridemia: an insight into the link between plasma insulin and triglyceride concentrations. J Clin Endocrinol Metab 2000, 85(9):3085-3088.
25. Hudgins L.C., Hellerstein M., Seidman C., Neese R., Diakun J., Hirsch J. Human fatty acid synthesis is stimulated by a eucaloric low fat, high carbohydrate diet. J Clin Invest 1996, 97(9):2081-2091.
26. Kang H., Greenson J.K., Omo J.T., et al. Metabolic syndrome is associated with greater histologic severity, higher carbohydrate, and lower fat diet in patients with NAFLD. Am J Gastroenterol 2006, 101(10):2247-2253.
27. Solga S., Alkhuraishe A.R., Clark J.M., et al. Dietary composition and nonalcoholic fatty liver disease. Dig Dis Sci 2004, 49(10):1578-1583.
28. Ryan M.C., Abbasi F., Lamendola C., Carter S., McLaughlin T.L. Serum alanine aminotransferase levels decrease further with carbohydrate than fat restriction in insulin-resistant adults. Diabetes Care 2007, 30(5):1075-1080.
29. Browning J.D., Baker J.A., Rogers T., Davis J., Satapati S., Burgess S.C. Short-term weight loss and hepatic triglyceride reduction: Evidence of a metabolic advantage with dietary carbohydrate restriction. Am J Clin Nutr 2011, 93(5):1048-1052.
30. Bacon B.R., Park C.H., Fowell E.M., McLaren C.E. Hepatic steatosis in rats fed diets with varying concentrations of sucrose. Fundam Appl Toxicol 1984, 4(5):819-826.
31. Dekker M.J., Su Q., Baker C., Rutledge A.C., Adeli K. Fructose: A highly lipogenic nutrient implicated in insulin resistance, hepatic steatosis, and the metabolic syndrome. Am J Physiol Endocrinol Metab 2010, 299(5):E685-E694.
32. Assy N., Nasser G., Kamayse I., et al. Soft drink consumption linked with fatty liver in the absence of traditional risk factors. Can J Gastroenterol 2008, 22(10):811-816.
33. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., et al. Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): A population based study. J Hepatol 2007, 47(5):711-717.
34. Thuy S., Ladurner R., Volynets V., et al. Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. J Nutr 2008, 138(8):1452-1455.
35. Ouyang X., Cirillo P., Sautin Y., et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol 2008, 48(6):993-999.
36. Le K.A., Ith M., Kreis R., et al. Fructose overconsumption causes dyslipidemia and ectopic lipid deposition in healthy subjects with and without a family history of type 2 diabetes. Am J Clin Nutr 2009, 89(6):1760-1765.
37. Collison K.S., Saleh S.M., Bakheet R.H., et al. Diabetes of the liver: The link between nonalcoholic fatty liver disease and HFCS-55. Obesity (Silver Spring) 2009, 17(11):2003-2013.
38. Anderson J.W., Randles K.M., Kendall C.W., Jenkins D.J. Carbohydrate and fiber recommendations for individuals with diabetes: A quantitative assessment and meta-analysis of the evidence. J Am Coll Nutr 2004, 23(1):5-17.
39. Roach P., Trautmann M., Arora V., Sun B., Anderson J.H. Improved postprandial blood glucose control and reduced nocturnal hypoglycemia during treatment with two novel insulin lispro-protamine formulations, insulin lispro mix25 and insulin lispro mix50. Clin Ther 1999, 21(3):523-534. Mix50 Study Group.
40. Solomon T.P., Haus J.M., Kelly K.R., et al. A low-glycemic index diet combined with exercise reduces insulin resistance, postprandial hyperinsulinemia, and glucose-dependent insulinotropic polypeptide responses in obese, prediabetic humans. Am J Clin Nutr 2010, 92(6):1359-1368.
41. Fraser A., Abel R., Lawlor D.A., Fraser D., Elhayany A. A modified Mediterranean diet is associated with the greatest reduction in alanine aminotransferase levels in obese type 2 diabetes patients: Results of a quasi-randomised controlled trial. Diabetologia 2008, 51(9):1616-1622.
42. Sathiaraj E., Chutke M., Reddy M.Y., et al. A case-control study on nutritional risk factors in non-alcoholic fatty liver disease in Indian population. Eur J Clin Nutr 2011, 65(4):533-537.
43. Vilar L., Oliveira C.P., Faintuch J., et al. High-fat diet: A trigger of non-alcoholic steatohepatitis?. Preliminary findings in obese subjects. Nutrition 2008, 24(11-12):1097-1102.
44. Panagiotakos D.B., Polychronopoulos E. The role of Mediterranean diet in the epidemiology of metabolic syndrome; converting epidemiology to clinical practice. Lipids Health Dis 2005, 4:7.
45. Kastorini C.M., Milionis H.J., Esposito K., Giugliano D., Goudevenos J.A., Panagiotakos D.B. The effect of Mediterranean diet on metabolic syndrome and its components: A meta-analysis of 50 studies and 534,906 individuals. J Am Coll Cardiol 2011, 57(11):1299-1313.
46. Gillingham L.G., Harris-Janz S., Jones P.J. Dietary monounsaturated Fatty acids are protective against metabolic syndrome and cardiovascular disease risk factors. Lipids 2011, 46(3):209-228.
47. Vallim T., Salter A.M. Regulation of hepatic gene expression by saturated fatty acids. Prostaglandins Leukot Essent Fatty Acids 2010, 82(4-6):211-218.
48. Musso G., Gambino R., De Michieli F., et al. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003, 37(4):909-916.
49. Lefevre M., Champagne C.M., Tulley R.T., Rood J.C., Most M.M. Individual variability in cardiovascular disease risk factor responses to low-fat and low-saturated-fat diets in men: Body mass index, adiposity, and insulin resistance predict changes in LDL cholesterol. Am J Clin Nutr 2005, 82(5):957-963.
50. Wang D., Wei Y., Pagliassotti M.J. Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis. Endocrinology 2006, 147(2):943-951.
51. van den Berg S.A., Guigas B., Bijland S., et al. High levels of dietary stearate promote adiposity and deteriorate hepatic insulin sensitivity. Nutr Metab (Lond) 2010, 7:24.
52. Tetri L.H., Basaranoglu M., Brunt E.M., Yerian L.M., Neuschwander-Tetri B.A. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. Am J Physiol Gastrointest Liver Physiol 2008, 295(5):G987-G995.
53. Martinez-Gonzalez M.A., Sanchez-Villegas A. The emerging role of Mediterranean diets in cardiovascular epidemiology: monounsaturated fats, olive oil, red wine or the whole pattern?. Eur J Epidemiol 2004, 19(1):9-13.
54. Alonso A., Ruiz-Gutierrez V., Martinez-Gonzalez M.A. Monounsaturated fatty acids, olive oil and blood pressure: Epidemiological, clinical and experimental evidence. Public Health Nutr 2006, 9(2):251-257.
55. Assy N., Nassar F., Nasser G., Grosovski M. Olive oil consumption and non-alcoholic fatty liver disease. World J Gastroenterol 2009, 15(15):1809-1815.
56. Clarke S.D., Jump D.B. Polyunsaturated fatty acid regulation of hepatic gene transcription. Lipids 1996, 31(suppl):S7-S11.
57. Kim H.J., Takahashi M., Ezaki O. Fish oil feeding decreases mature sterol regulatory element-binding protein 1 (SREBP-1) by down-regulation of SREBP-1c mRNA in mouse liver. A possible mechanism for down-regulation of lipogenic enzyme mRNAs. J Biol Chem 1999, 274(36):25892-25898.
58. Benatti P., Peluso G., Nicolai R., Calvani M. Polyunsaturated fatty acids: Biochemical, nutritional and epigenetic properties. J Am Coll Nutr Aug 2004, 23(4):281-302.
59. Capanni M., Calella F., Biagini M.R., et al. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: A pilot study. Aliment Pharmacol Ther 2006, 23(8):1143-1151.
60. Spadaro L., Magliocco O., Spampinato D., et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Dig Liver Dis 2008, 40(3):194-199.
61. Tanaka N., Sano K., Horiuchi A., Tanaka E., Kiyosawa K., Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol 2008, 42(4):413-418.
62. Zuliani G., Galvani M., Leitersdorf E., Volpato S., Cavalieri M., Fellin R. The role of polyunsaturated fatty acids (PUFA) in the treatment of dyslipidemias. Curr Pharm Des 2009, 15(36):4087-4093.
63. Ebrahimi M., Ghayour-Mobarhan M., Rezaiean S., et al. Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity. Acta Cardiol 2009, 64(3):321-327.
64. Tapsell L.C., Gillen L.J., Patch C.S., et al. Including walnuts in a low-fat/modified-fat diet improves HDL cholesterol-to-total cholesterol ratios in patients with type 2 diabetes. Diabetes Care 2004, 27(12):2777-2783.
65. Araya J., Rodrigo R., Videla L.A., et al. Increase in long-chain polyunsaturated fatty acid n-6/n-3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004, 106(6):635-643.
66. Tovar A.R., Torre-Villalvazo I., Ochoa M., et al. Soy protein reduces hepatic lipotoxicity in hyperinsulinemic obese Zucker fa/fa rats. J Lipid Res 2005, 46(9):1823-1832.
67. Mikkelsen P.B., Toubro S., Astrup A. Effect of fat-reduced diets on 24-h energy expenditure: Comparisons between animal protein, vegetable protein, and carbohydrate. Am J Clin Nutr 2000, 72(5):1135-1141.
68. Ahmed F.E. Effect of diet on progression of chronic renal disease. J Am Diet Assoc 1991, 91(10):1266-1270.
69. Meyer T.W., Anderson S., Brenner B.M. Dietary protein intake and progressive glomerular sclerosis: The role of capillary hypertension and hyperperfusion in the progression of renal disease. Ann Intern Med 1983, 98(5 pt 2):832-838.
70. Hill J.O., Thompson H., Wyatt H. Weight maintenance: What's missing?. J Am Diet Assoc 2005, 105(5 suppl 1):S63-S66.
71. Mann T., Tomiyama A.J., Westling E., Lew A.M., Samuels B., Chatman J. Medicare's search for effective obesity treatments: Diets are not the answer. Am Psychol 2007, 62(3):220-233.
72. Phelan S., Wing R.R., Loria C.M., Kim Y., Lewis C.E. Prevalence and predictors of weight-loss maintenance in a biracial cohort: Results from the coronary artery risk development in young adults study. Am J Prev Med 2010, 39(6):546-554.
73. Hindle L., Carpenter C. An exploration of the experiences and perceptions of people who have maintained weight loss. J Hum Nutr Diet 2011, 24(4):342-350.
74. Pillai A.A., Rinella M.E. Non-alcoholic fatty liver disease: Is bariatric surgery the answer?. Clin Liver Dis 2009, 13(4):689-710.
75. Mummadi R.R., Kasturi K.S., Chennareddygari S., Sood G.K. Effect of bariatric surgery on nonalcoholic fatty liver disease: Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008, 6(12):1396-1402.
76. Hamdy O., Zwiefelhofer D. Weight management using a meal replacement strategy in type 2 diabetes. Curr Diab Rep 2010, 10(2):159-164.
77. Centis E., Marzocchi R., Di Domizio S., Ciaravella M.F., Marchesini G. The effect of lifestyle changes in non-alcoholic fatty liver disease. Dig Dis 2010, 28(1):267-273.
78. Moscatiello S., Di Luzio R., Bugianesi E., et al. Cognitive-behavioral treatment of nonalcoholic fatty liver disease: A propensity score-adjusted observational study. Obesity (Silver Spring) 2011, 19(4):763-770.
79. Greaves C.J., Sheppard K.E., Abraham C., et al. Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions. BMC Public Health 2011, 11(1):119.
80. Boule N.G., Haddad E., Kenny G.P., Wells G.A., Sigal R.J. Effects of exercise on glycemic control and body mass in type 2 diabetes mellitus: a meta-analysis of controlled clinical trials. JAMA 2001, 286(10):1218-1227.
81. Zelber-Sagi S., Nitzan-Kaluski D., Goldsmith R., et al. Role of leisure-time physical activity in nonalcoholic fatty liver disease: A population-based study. Hepatology 2008, 48(6):1791-1798.
82. St George A., Bauman A., Johnston A., Farrell G., Chey T., George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009, 50(1):68-76.
83. Kistler K.D., Brunt E.M., Clark J.M., Diehl A.M., Sallis J.F., Schwimmer J.B. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic Fatty liver disease. Am J Gastroenterol 2011, 106(3):460-468.
84. Devries M.C., Samjoo I.A., Hamadeh M.J., Tarnopolsky M.A. Effect of endurance exercise on hepatic lipid content, enzymes, and adiposity in men and women. Obesity (Silver Spring) 2008, 16(10):2281-2288.
85. Bassuk S.S., Manson J.E. Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease. J Appl Physiol 2005, 99(3):1193-1204.
86. Lavine J.E. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study. J Pediatr 2000, 136(6):734-738.
87. Sanyal A.J., Chalasani N., Kowdley K.V., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010, 362(18):1675-1685.
88. Arendt B.M., Allard J.P. Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: Is the combination required?. Am J Gastroenterol 2011, 106(1):78-80.
89. Sanyal A.J., Mofrad P.S., Contos M.J., et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol 2004, 2(12):1107-1115.
90. Kugelmas M., Hill D.B., Vivian B., Marsano L., McClain C.J. A pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003, 38(2):413-419.
91. Foster T., Budoff M.J., Saab S., Ahmadi N., Gordon C., Guerci A.D. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: The St Francis Heart Study randomized clinical trial. Am J Gastroenterol 2011, 106(1):71-77.
92. Harrison S.A., Torgerson S., Hayashi P., Ward J., Schenker S. Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003, 98(11):2485-2490.
93. Miller E.R., Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., Guallar E. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005, 142(1):37-46.
94. Abdelmalek M.F., Angulo P., Jorgensen R.A., Sylvestre P.B., Lindor K.D. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: Results of a pilot study. Am J Gastroenterol 2001, 96(9):2711-2717.
95. Kathirvel E., Morgan K., Nandgiri G., et al. Betaine improves nonalcoholic fatty liver and associated hepatic insulin resistance: A potential mechanism for hepatoprotection by betaine. Am J Physiol Gastrointest Liver Physiol 2010, 299(5):G1068-G1077.
96. Wang Z., Yao T., Pini M., Zhou Z., Fantuzzi G., Song Z. Betaine improved adipose tissue function in mice fed a high-fat diet: A mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease. Am J Physiol Gastrointest Liver Physiol 2010, 298(5):G634-G642.
97. Abdelmalek M.F., Sanderson S.O., Angulo P., et al. Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo-controlled trial. Hepatology 2009, 50(6):1818-1826.
98. Abu-Shanab A., Quigley E.M. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol 2010, 7(12):691-701.
99. Loguercio C., De Simone T., Federico A., et al. Gut-liver axis: A new point of attack to treat chronic liver damage?. Am J Gastroenterol 2002, 97(8):2144-2146.
100. Loguercio C., Federico A., Tuccillo C., et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005, 39(6):540-543.
101. Sahebkar A. Potential efficacy of ginger as a natural supplement for nonalcoholic fatty liver disease. World J Gastroenterol 2011, 17(2):271-272.
102. Mohamed Salih S., Nallasamy P., Muniyandi P., Periyasami V., Carani Venkatraman A. Genistein improves liver function and attenuates non-alcoholic fatty liver disease in a rat model of insulin resistance. J Diabetes 2009, 1(4):278-287.
103. Yalniz M., Bahcecioglu I.H., Kuzu N., et al. Preventive role of genistein in an experimental non-alcoholic steatohepatitis model. J Gastroenterol Hepatol 2007, 22(11):2009-2014.
104. Kim M.H., Kang K.S., Lee Y.S. The inhibitory effect of genistein on hepatic steatosis is linked to visceral adipocyte metabolism in mice with diet-induced non-alcoholic fatty liver disease. Br J Nutr 2010, 104(9):1333-1342.
105. Casiglia E., Spolaore P., Ginocchio G., Ambrosio G.B. Unexpected effects of coffee consumption on liver enzymes. Eur J Epidemiol 1993, 9(3):293-297.
106. Sharp D.S., Benowitz N.L. Re: "Alcohol, smoking, coffee, and cirrhosis" and "coffee and serum gamma-glutamyltransferase: A study of self-defense officials in Japan.". Am J Epidemiol 1995, 141(5):480-482.
107. Modi A.A., Feld J.J., Park Y., et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology 2010, 51(1):201-209.
108. Costentin C.E., Roudot-Thoraval F., Zafrani E.S., et al. Association of caffeine intake and histological features of chronic hepatitis C. J Hepatol 2011, 54(6):1123-1129.
109. Ruhl C.E., Everhart J.E. Coffee and tea consumption are associated with a lower incidence of chronic liver disease in the United States. Gastroenterology 2005, 129(6):1928-1936.